An Overview of the BR-002 Trial in Breast Cancer

Julia White, MD
Published Online: March 27, 2014
Julia White, MD, professor, director, Breast Radiation Oncology, vice chair, Clinical Research, The Ohio State University Comprehensive Cancer Center, discusses the BR-002 trial, which will evaluate the rate of complete tumor ablation of breast cancers that are less than or equal to 2 centimeters.

Clinical Pearls:
  • This trial seeks to confirm that a local intervention does not change the outcome of a patient
  • Participants of the trial will be randomized to ablation or standard treatment
  • Women are only qualified for the trial if they are responding to chemotherapy or are in their first line of chemotherapy​


Related Articles
Joan Lunden discusses the diagnostic approach that led to the early detection of triple-negative breast cancer, which was undetected by mammogram and 3D mammogram but was detected with ultrasound.
In an analysis of more than 17,000 patients with breast cancer, who are at risk for a genetic mutation, subjects were as likely to have a mutation in a gene other than BRCA1 and BRCA2 as they were to have these common mutations.
Christopher Twelves, MD, Professor of Clinical Cancer Pharmacology and Oncology, University of Leeds, discusses a pooled analysis of eribulin for the treatment of patients with breast cancer.
Researchers will dissect topline results from the MARIANNE trial in an effort to understand why T-DM1 failed to triumph as a first-line treatment in the metastatic setting for patients with advanced HER2-positive breast cancer despite the promise of earlier findings.
JTT Articles
CD19-Targeted Agents Continue to Show Positive Outcomes
Management of Hepatocellular Cancer
External Resources

AJMC
Cure
HCPLive
OncLive
PainLive
Pharmacy Times
Physicians' Education Resource
Physician's Money Digest
Internal Resources

Articles
Fellows
Publications
Targeted Communications
Resources
Connect With Us:

About Us
Advertise
Contact Us
Privacy Policy
Terms & Conditions
Intellisphere, LLC
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-716-4747

Copyright TargetedOnc 2013
Intellisphere, LLC. All Rights Reserved.